Rivaroxaban for Treatment of Deep Vein Thrombosis, Pulmonary Embolism
Rivaroxaban (Xarelto) is an oral anticoagulant for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. Rivaroxaban is the first and only oral anticoagulant approved to treat DVT and PE without the need for injections or routine blood monitoring, and has the broadest profile of any of the new oral anticoagulants in the U.S. market today or coming to market in the foreseeable future.
Rivaroxaban provides a single-drug treatment option from the moment of diagnosis through the completion of therapy, and in the initial treatment phase, it can cut a patient's risk of major bleeding by nearly half.
Rivaroxaban is approved to treat patients with DVT or PE at a dose of 15 mg twice daily for three weeks, followed by 20 mg once daily for the remaining treatment period. Rivaroxaban is also approved to reduce the risk of recurrence of DVT and PE at a dose of 20 mg once daily following an initial six months of treatment for acute venous thromboembolism.
Rivaroxaban is broadly reimbursed for more than 90 percent of commercial and Medicare health plan members, with the majority covered at the lowest branded co-pay. To date, more than 2.5 million patients have received rivaroxaban worldwide and more than 760,000 prescriptions have been written for rivaroxaban in the United States.
Janssen Pharmaceuticals Inc. holds U.S. marketing rights for Xarelto, and is supported by the Bayer HealthCare U.S. sales force in designated hospital accounts.
For more information: www.janssenpharmaceuticalsinc.com